Literature DB >> 8403483

Epidermolysis bullosa acquisita occurring in association with systemic lupus erythematosus.

P M McHenry1, J H Dagg, M J Tidman, R S Lever.   

Abstract

A 77-year-old retired male physician with a 6-year history of systemic lupus erythematosus (SLE) developed a mechanobullous eruption, the features of which were clinically and immunopathologically consistent with a diagnosis of 'classical' epidermolysis bullosa acquisita (EBA). As EBA shares immunopathological findings with a number of cases reported as the 'bullous eruption of SLE', the clinical findings commonly recognized as 'classical EBA' may, in patients with SLE, represent a specific subset of the bullous eruption of SLE rather than a separate diagnostic entity. There are few reports in the literature describing classical EBA in patients with SLE. Findings in this patient add further support to the suggestion that EBA occurring in association with SLE, represents a subset of the bullous eruption of SLE, the clinical features of which may be modified by genetic susceptibility or disease activity.

Entities:  

Mesh:

Year:  1993        PMID: 8403483     DOI: 10.1111/j.1365-2230.1993.tb02224.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  3 in total

Review 1.  Neutrophilic skin lesions in autoimmune connective tissue diseases: nine cases and a literature review.

Authors:  Estelle Hau; Marie-Dominique Vignon Pennamen; Maxime Battistella; Anne Saussine; Maud Bergis; Benedicte Cavelier-Balloy; Michel Janier; Florence Cordoliani; Martine Bagot; Michel Rybojad; Jean-David Bouaziz
Journal:  Medicine (Baltimore)       Date:  2014-12       Impact factor: 1.889

2.  Vesiculobullous diseases in relation to lupus erythematosus.

Authors:  Suthinee Rutnin; Kumutnart Chanprapaph
Journal:  Clin Cosmet Investig Dermatol       Date:  2019-09-04

Review 3.  Humoral Epitope Spreading in Autoimmune Bullous Diseases.

Authors:  Dario Didona; Giovanni Di Zenzo
Journal:  Front Immunol       Date:  2018-04-17       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.